Massachusetts Couple Sentenced to Prison for Importing Misbranded Drugs From China and Selling Them to Customers in U.S. for Performance Enhancing Purposes

BOSTON - A Massachusetts couple have been sentenced in federal court in Boston for conspiring to introduce misbranded drugs into interstate commerce with intent to defraud and mislead.

Chenguang Gong, 43, and Yalan Tang, 45, both of Belmont, Mass., were each sentenced by U.S. District Court Richard G. Stearns to one year and one day in prison, to be followed by one year of supervised release. In January 2026, the defendants pleaded guilty to one count of conspiring to introduce misbranded drugs into interstate commerce with intent to defraud and mislead.

From at least 2016 through 2020, Gong and Tang imported misbranded drugs from China, using multiple post office boxes, falsified addressees and other deceptive conduct to avoid detection. After receiving the drugs from China, Gong and Tang repackaged the materials and sold them to customers-falsely labeling their products as "For Research Purposes Only," when, in fact, Gong and Tang knew and understood that their customers would ingest or inject the drugs for performance enhancing purposes. The performance enhancing drugs sold by Gong and Tang included drugs commonly used by bodybuilders and athletes to enhance muscle growth and strength, improve cardiovascular performance and improve endurance. Other drugs sold by Gong and Tang improved cosmetic appearance, prevented or slowed symptoms of aging, improved cognitive function and improved sexual performance.

Over the course of their scheme, Gong and Tang's gross sales exceeded $2.5 million and Gong and Tang earned profits of more than $600,000.

United States Attorney Leah B. Foley and Fernando McMillan, Special Agent in Charge of the Food and Drug Administration, Office of Criminal Investigations, New York Field Office made the announcement today. The U.S. Anti-Doping Agency provided valuable assistance. Assistant U.S. Attorney Chris Looney and Deputy Chief of the Health Care Fraud Unit Leslie Wright prosecuted the case.